CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

By screening a custom library of shRNAs directed toward known drug targets in a genetically defined Myc-driven hepatocellular carcinoma model, Huang et al. identified Cdk9 as required for disease maintenance. Pharmacological or shRNA-mediated CDK9 inhibition led to robust anti-tumor effects that correlated with MYC expression levels and depended on the role that both CDK9 and MYC exert in transcription elongation. This study proposes CDK9 inhibition as a therapeutic strategy for MYC-overexpressing liver tumors and highlights the relevance of transcription elongation in the addiction of cancer cells to MYC.

• Publication year

  2014

• Venue

  Genes & Development

• Publication date

  2014-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/gad.244368.114PMID 25128497PMCID 4197965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

  2014cited by this paper
• An overview of MYC and its interactome.

  2014influential reference
• Direct in Vivo RNAi Screen Unveils Myosin IIa as a Tumor Suppressor of Squamous Cell Carcinomas

  2014cited by this paper
• Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

  2014cited by this paper
• Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

  2014cited by this paper
• Exploration of liver cancer genomes

  2014cited by this paper
• p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer.

  2014cited by this paper
• Transcriptional regulation and its misregulation in disease.

  2013cited by this paper
• FOR THE EXPRESSION

  2013cited by this paper
• An optimized microRNA backbone for effective single-copy RNAi.

  2013cited by this paper
• Medical therapies for hepatocellular carcinoma: a critical view of the evidence

  2013influential reference
• Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013influential reference
• Deregulations in the Cyclin-Dependent Kinase-9-Related Pathway in Cancer: Implications for Drug Discovery and Development

  2013cited by this paper
• A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

  2012cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• On using functional genetics to understand breast cancer biology.

  2012cited by this paper
• Annotating MYC oncogene status with 89Zr-transferrin imaging

  2012cited by this paper
• The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012influential reference
• Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.

  2012cited by this paper
• c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

  2012cited by this paper
• RNA polymerase II elongation control.

  2012cited by this paper
• Transcriptional amplification in tumor cells with elevated c-Myc.

  2012influential reference
• Functional genomics identifies therapeutic targets for MYC-driven cancer

  2012cited by this paper
• Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

  2012cited by this paper
• An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

  2011influential reference
• Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

  2011influential reference
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011influential reference
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011influential reference
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.

  2010cited by this paper
• c-Myc regulates transcriptional pause release.

  2010influential reference
• 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

  2010cited by this paper
• Using functional genetics to understand breast cancer biology.

  2010cited by this paper
• Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

  2009cited by this paper
• Standardized methods for the production of high specific-activity zirconium-89.

  2009cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

  2009cited by this paper
• The expression of exogenous genes in macrophages: obstacles and opportunities.

  2009cited by this paper
• A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.

  2008influential reference
• Modelling Myc inhibition as a cancer therapy

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008influential reference
• Nascent RNA Sequencing Reveals Widespread Pausing and Divergent Initiation at Human Promoters

  2008cited by this paper
• Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC

  2007cited by this paper
• Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription

  2007influential reference
• Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis

  2006influential reference
• Hepatocellular carcinoma pathogenesis: from genes to environment

  2006cited by this paper
• Controlling the elongation phase of transcription with P-TEFb.

  2006cited by this paper
• Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.

  2006cited by this paper
• Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line

  2005cited by this paper
• Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells

  2004cited by this paper
• MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets

  2003cited by this paper
• c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis

  2003cited by this paper
• PTK2 and EIF3S3 genes may be amplification targets at 8q23‐q24 and are associated with large hepatocellular carcinomas

  2003cited by this paper
• An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

  2003cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

  2002cited by this paper
• Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

  2001cited by this paper
• c-Myc Mediates Activation of the cad Promoter via a Post-RNA Polymerase II Recruitment Mechanism*

  2001cited by this paper
• The transcriptional program of a human B cell line in response to Myc.

  2001cited by this paper
• Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.

  2001cited by this paper
• Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

  2000cited by this paper
• Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

  2000cited by this paper
• Mammalian Cdc7–Dbf4 protein kinase complex is essential for initiation of DNA replication

  1999cited by this paper
• RNA polymerase II elongation control.

  1998cited by this paper
• Transferrin receptor expression in rat liver: Immunohistochemical and biochemical analysis of the effect of age and iron storage

  1990cited by this paper
• Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29

  1982cited by this paper
• Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

  1982cited by this paper

• Alternative Strategies of Reducing MYC Expression for the Treatment of Cancers.

  2026cites this paper
• KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

  2025cites this paper
• Fluoxetine promotes lysosome biogenesis via regulation of a RIOK2-TFEB axis

  2025cites this paper
• CDK7 is a novel therapeutic target in fibrolamellar carcinoma

  2025cites this paper
• CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer

  2025cites this paper
• shRNAI: A deep neural network for the design of highly potent shRNAs

  2025cites this paper
• The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions.

  2025cites this paper
• Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

  2025cites this paper
• Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer

  2025cites this paper
• KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regression

  2025influential citation
• Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer

  2025cites this paper
• Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC

  2025cites this paper
• Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma

  2024cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2024cites this paper
• CDK9 inhibitors for the treatment of solid tumors.

  2024cites this paper
• PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer.

  2024cites this paper
• Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer

  2024cites this paper
• Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma

  2024cites this paper
• Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma.

  2024cites this paper
• The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

  2024cites this paper
• Therapeutic index of targeting select chromatin complexes in human cancer patients.

  2024cites this paper
• PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer

  2024cites this paper
• MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

  2024cites this paper
• Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response

  2023cites this paper
• Selective inhibition of CDK9 in triple negative breast cancer

  2023cites this paper
• Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

  2023cites this paper
• Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

  2023cites this paper
• Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications

  2023cites this paper
• The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma

  2023cites this paper
• Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: past, present and future perspectives

  2023cites this paper
• MYC in liver cancer: mechanisms and targeted therapy opportunities

  2023cites this paper
• RNAPII-dependent ATM signaling at collisions with replication forks

  2023cites this paper
• Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications

  2023cites this paper
• T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

  2023cites this paper
• ERK2 stimulates MYC transcription by anchoring CDK9 to the MYC promoter in a kinase activity–independent manner

  2023cites this paper
• Examination of the Impact of Triazole Position within Linkers on Solubility and Lipophilicity of a CDK9 Degrader Series.

  2023cites this paper
• Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers

  2023cites this paper
• Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

  2023cites this paper
• Identification of a diketopiperazine‐based O‐GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition

  2023cites this paper
• Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.

  2023cites this paper
• Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies

  2023cites this paper
• DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.

  2023cites this paper
• <scp> m ⁶ A </scp> promotes planarian regeneration

  2023cites this paper
• m6A promotes planarian regeneration

  2023cites this paper
• Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery.

  2023cites this paper
• The effects of MYC on tumor immunity and immunotherapy

  2023cites this paper
• Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer

  2023cites this paper
• Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition

  2023cites this paper
• CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells

  2023cites this paper
• MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer

  2023cites this paper
• Nature-Derived Compounds as Potential Bioactive Leads against CDK9-Induced Cancer: Computational and Network Pharmacology Approaches

  2022cites this paper
• Evaluation of novel CDK-inhibitors in combination with apoptosis-modulating agents for the treatment of colorectal cancer

  2022cites this paper
• MYC and therapy resistance in cancer: risks and opportunities

  2022cites this paper
• Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma

  2022cites this paper
• Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery

  2022cites this paper
• Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma

  2022cites this paper
• Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.

  2022cites this paper
• Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi

  2022cites this paper
• Design, synthesis, and biological evaluation of (E)-N'-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors

  2022cites this paper
• Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines

  2022cites this paper
• A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

  2022influential citation
• MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer

  2022cites this paper
• Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

  2022cites this paper
• A New Insight into MYC Action: Control of RNA Polymerase II Methylation and Transcription Termination

  2022cites this paper
• CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma

  2022cites this paper
• Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

  2021cites this paper
• Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.

  2021cites this paper
• Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

  2021cites this paper
• Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy

  2021cites this paper
• Rationale for MYC imaging and targeting in pancreatic cancer

  2021cites this paper
• Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells

  2021cites this paper
• m6A-mediated Cell-cell Communication Controls Planarian Regeneration

  2021cites this paper
• MYC protein interactors in gene transcription and cancer

  2021cites this paper
• The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

  2021cites this paper
• Identi cation of Prognostic Biomarkers of Ewing Sarcoma using Bioinformatics Analysis and Experiments

  2021cites this paper
• Targeting CDK9 for the Treatment of Glioblastoma

  2021cites this paper
• Identi cation of Prognostic Biomarkers of Ewing Sarcoma using Bioinformatics Analysis and Experiments

  2021cites this paper
• The long journey to bring a Myc inhibitor to the clinic

  2021cites this paper
• Exploring liver cancer biology through functional genetic screens

  2021cites this paper
• Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters.

  2021influential citation
• Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9

  2021cites this paper
• Localized inhibition of protein phosphatase 1 by NUAK1 promotes spliceosome activity and reveals a MYC-sensitive feedback control of transcription

  2021cites this paper
• Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition

  2020cites this paper
• Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

  2020cites this paper
• Vitamin B6 Addiction in Acute Myeloid Leukemia.

  2020cites this paper
• Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription

  2020cites this paper
• Target gene-independent functions of MYC oncoproteins

  2020cites this paper
• Synthetic lethality: a promising therapeutic strategy for hepatocellular carcinoma.

  2020cites this paper
• CDK9 is dispensable for YAP‐driven hepatoblastoma development

  2020cites this paper
• Super elongation complex as a targetable dependency in diffuse midline glioma

  2020cites this paper
• Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity

  2020cites this paper
• Keeping RNA polymerase II on the run: Functions of MLL fusion partners in transcriptional regulation.

  2020cites this paper
• CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.

  2020cites this paper
• Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.

  2020cites this paper
• Targeting CDK9: A novel biomarker in the treatment of endometrial cancer

  2020cites this paper
• Development of synthetic lethality in cancer: molecular and cellular classification

  2020cites this paper
• The SUMO pathway in pancreatic cancer: insights and inhibition

  2020cites this paper
• Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

  2020influential citation